top biopharmaceuticals for glp-1 medication Women with a common hormonal disorder have few good treatment options. Could drugs help? Shortages improve for Lilly's GLP-1

GLP-1 therapy injections represent a groundbreaking advancement in the treatment of obesity and significant weight loss

Recently, BMS terminated the Phase III RELATIVITY-123 trial investigating the combination of Opdivo and the LAG-3 antibody relatlimab in a fixed dose for patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

GLP-1 therapies are also being folded more and more into individual care plans so they can improve effectiveness and better clinical results

Compounded Semaglutide (GLP-1) is a once-weekly injectable medication that mimics a natural hormone involved in appetite regulation and blood sugar control

These companies currently offer five GLP-1 drugs approved for type 2 diabetes, with four also approved for various cardiovascular conditions

The Phase III clinical SURMOUNT-1 (NCT04184622) for tirzepatide, is expected to be completed in the first half of 2024